Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient

European Journal of Cancer

Volumn 67, Issue , 2016, Pages 66-72

  Herz, Saskia ^a,b   Höfer, Thomas ^a,b   Papapanagiotou, Matina ^a,b   Leyh, Julia Christina ^a,b   Meyenburg, Sarah ^a,b   Schadendorf, Dirk ^a,b   Ugurel, Selma ^a,b   Roesch, Alexander ^a,b   Livingstone, Elisabeth ^a,b   Schilling, Bastian ^a,b   Franklin, Cindy ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CTLA 4; Kidney failure; Melanoma; Organ transplantation; PD 1

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; IPILIMUMAB; MELPHALAN; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; PREDNISONE; TACROLIMUS; UREA; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; AMELANOTIC MELANOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEEK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPASSIONATE USE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROCHEMOTHERAPY; END STAGE RENAL DISEASE; FACE TUMOR; FOOT; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN-TRANSIT METASTASIS; INGUINAL LYMPH NODE; INSOMNIA; KIDNEY DISEASE; KIDNEY FUNCTION TEST; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOWER LEG; LUNG METASTASIS; LYMPH NODE DISSECTION; MALE; METASTATIC MELANOMA; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIMODALITY CANCER THERAPY; NECK; NECK DISSECTION; NEURASTHENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTIDECTOMY; POLYNEUROPATHY; PRIORITY JOURNAL; SCALP TUMOR; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SKIN METASTASIS; SKULL; SOFT TISSUE METASTASIS; SYSTEMIC THERAPY; THIGH; THORAX RADIOGRAPHY; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; UREA BLOOD LEVEL; WIDE EXCISION; ANTAGONISTS AND INHIBITORS; CASE REPORT; COMPLICATION; GRAFT REJECTION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MELANOMA; PATHOLOGY; PATIENT SAFETY; SECONDARY; SKIN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MELANOMA; MIDDLE AGED; PATIENT SAFETY; PREDNISOLONE; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TACROLIMUS;

EID: 84985993718     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.07.026     Document Type: Article

References (27)

1. [1] Schadendorf, D., Fisher, D.E., Garbe, C., Gershenwald, J.E., Grob, J.-J., Halpern, A., et al. Melanoma. Nat Rev Dis Prim, 2015, 15003.
2. [2] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
3. [3] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
4. [4] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
5. [5] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
6. [6] Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
7. [7] Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
8. [8] Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
9. [9] Girndt, M., Trocchi, P., Scheidt-Nave, C., Markau, S., Stang, A., The prevalence of renal failure. Dtsch Arztebl Int 113 (2016), 85–91.
10. [10] Marple, J.T., MacDougall, M., Development of malignancy in the end-stage renal disease patient. Semin Nephrol 13 (1993), 306–314.
11. [11] Gallagher, M.P., Kelly, P.J., Jardine, M., Perkovic, V., Cass, A., Craig, J.C., et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 21 (2010), 852–858.
12. [12] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
13. [13] Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
14. [14] Lipson, E.J., Bodell, M.A., Kraus, E.S., Sharfman, W.H., Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 32 (2014), e69–e71.
15. [15] Ranganath, H.A., Panella, T.J., Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother, 38, 2015, 211.
16. [16] Morales, R.E., Shoushtari, A.N., Walsh, M.M., Grewal, P., Lipson, E.J., Carvajal, R.D., Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer, 3, 2015, 22.
17. [17] Spain, L., Higgins, R., Gopalakrishnan, K., Turajlic, S., Gore, M., Larkin, J., Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 27 (2016), 1135–1137.
18. [18] Lipson, E.J., Bagnasco, S.M., Moore, J. Jr., Jang, S., Patel, M.J., Zachary, A.A., et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 374 (2016), 896–898.
19. [19] Alhamad, T., Venkatachalam, K., Linette, G.P., Brennan, D.C., Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transpl 16 (2016), 1332–1333.
20. [20] Hofmann, L., Forschner, A., Loquai, C., Goldinger, S.M., Zimmer, L., Ugurel, S., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 190–209.
21. [21] Zhang, T., Fresnay, S., Welty, E., Sangrampurkar, N., Rybak, E., Zhou, H., et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transpl 11 (2011), 1599–1609.
22. [22] Morita, M., Fujino, M., Jiang, G., Kitazawa, Y., Xie, L., Azuma, M., et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am J Transpl 10 (2010), 40–46.
23. [23] Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer cell 27 (2015), 450–461.
24. [24] Ito, T., Ueno, T., Clarkson, M.R., Yuan, X., Jurewicz, M.M., Yagita, H., et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol 174 (2005), 6648–6656.
25. [25] Blazar, B.R., Carreno, B.M., Panoskaltsis-Mortari, A., Carter, L., Iwai, Y., Yagita, H., et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171 (2003), 1272–1277.
26. [26] Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., Lanfranco, A.R., Braunstein, I., Kobayashi, S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25 (2005), 9543–9553.
27. [27] Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367 (2012), 329–339.